MetaVia Inc.
MTVAAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jul 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 18, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 27, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 6, 2026 |
| Maxim Group | maintain | Buy | May 19, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 16, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 21, 2025 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 6, 2026 | $-0.90 | $-0.82 | — | — |
| May 14, 2026 | $-0.79 | $-0.76 | — | — |
| Mar 26, 2026 | $1.01 | $-2.06 | — | — |
| Nov 6, 2025 | $-1.54 | $-2.86 | — | — |
| Aug 7, 2025 | $-2.86 | $-3.52 | — | — |
| May 14, 2025 | $-3.96 | $-6.27 | — | — |
| Mar 27, 2025 | $-1.76 | $-0.72 | — | — |
| Nov 7, 2024 | $-6.05 | $-0.82 | — | — |
News
DA-1726 Also Demonstrated Statistically Significant 13.5% Placebo-Adjusted Weight Loss and Reduced Mean HbA1c from 5.79% to 5.33% in Participants Without Diabetes No New Gastrointestinal Adverse Events Were Reported After Week 9 Through Day 109, with No Gastrointestinal Adverse Events Leading to Study Discontinuation Full Part 3A and Part 3B Data Expected in the First Quarter of 2027 Results Support 48-Week, Non-Biopsy Phase 2 Study of DA-1726 in Up to 150 Patients with MetALD and ALD, Targeted …
CAMBRIDGE, Mass., Oct. 28, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial of DA-1726, a novel dual oxyntomodulin (OXM) analog targeting both GLP-1 (GLP1R) and glucagon (GCGR) receptors, has been accepted for an oral presentation at the Precision Liver Symposium 2026, taking place November 4, 2026, in Denver, Colorado.
Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development Deep Expertise in Dual GLP-1/Glucagon Receptor Agonist Development, Including Pemvidutide CAMBRIDGE, Mass., Oct. 13, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the appointment of Sarah Browne, M.D.
Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726 CAMBRIDGE, Mass., Sept. 9, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced results from a preclinical tissue distribution study demonstrating that DA-1726-derived radioactivity is slowly a…